A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
Commentary|Videos|June 16, 2024
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Author(s)Sujith Samarasinghe, MD
Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.
Advertisement
Sujith Samarasinghe, MD, consultant pediatric hematologist, Great Ormond St. Hospital, discusses key results from the phase 2 ALLTOGETHER 1 DS trial evaluating the use of first-line blinatumomab (Blincyto) as chemotherapy replacement for patients with Down Syndrome B-cell acute lymphoblastic leukemia (B-ALL) that were presented at the
Advertisement
Related to this article
David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia.
The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.
A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
The OncFive: Top Oncology Articles for the Week of 9/14/2026
3
OncLive Weekly News Quiz (9/19/2026): Did You Catch the Latest NETs, Lung, Mastocytosis, and Pancreatic Cancer News?
4
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
5